<I>HELICOBACTER PYLORI, </I>DOLOR TORACICO Y SISTEMA NERVIOSO AUTONOMO





HELICOBACTER PYLORI, DOLOR TORACICO Y SISTEMA NERVIOSO AUTONOMO

(especial para SIIC © Derechos reservados)
En este artículo, explicamos el papel de la infección por Helicobacter pylori y el sistema nervioso autónomo en la patogenia de los trastornos funcionales del tubo digestivo y el dolor torácico.
Autor:
Jacek Budzynski
Columnista Experto de SIIC

Institución:
Department of Gastroenterology, Vascular Diseases and Internal Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz


Artículos publicados por Jacek Budzynski
Recepción del artículo
28 de Marzo, 2006
Aprobación
3 de Abril, 2006
Primera edición
29 de Junio, 2007
Segunda edición, ampliada y corregida
7 de Junio, 2021

Resumen
El papel de la infección por Helicobacter pylori en las enfermedades gástricas está bien documentado, pero se debate aún su importancia en la patogenia de las enfermedades esofágicas y algunos trastornos fuera del tubo digestivo. Este artículo intenta revisar cierta información nueva relativa a la influencia de Helicobacter pylori sobre la actividad del sistema nervioso autónomo (SNA) como mecanismo de acción indirecta sobre el tubo digestivo y el sistema circulatorio. El efecto de Helicobacter pylori sobre el SNA puede ser el resultado de un efecto neurotóxico directo, la activación de procesos inflamatorios en los nervios, una deficiencia de microelementos y la estimulación inducida por los síntomas originados en los sistemas digestivo y circulatorio. El desequilibrio del SNA en los pacientes que presentan una infección por Helicobacter pylori puede afectar la motilidad esofágica, el grado del reflujo del contenido gástrico en el esófago, la evacuación gástrica, la acidez del jugo gástrico y el flujo sanguíneo de la mucosa. Estos trastornos provocan dispepsia, pirosis y dolor torácico. Este último requiere especial atención, debido a un resultado fatal potencial cuando el diagnóstico es erróneo. Puede ser difícil determinar el origen del dolor torácico, el que además puede ser multifactorial. Se deben tener en cuenta los trastornos esofágicos y cardíacos, así como las interrelaciones entre estos órganos, que dependen de los factores de riesgo en común para las enfermedades, reflejos vagales, una disminución del umbral para el dolor y los efectos adversos de los fármacos utilizados en el tratamiento de la angina de pecho.

Palabras clave
helicobacter pylori, variabilidad de la frecuencia cardíaca, sistema nervioso autónomo, dolor torácico, tracto digestivo


Artículo completo

(castellano)
Extensión:  +/-10.56 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
Helicobacter pylori infection role in stomach diseases is well documented, but its significance in the pathogenesis of esophageal diseases and extra-digestive tract disorders is still discussed. This paper is addressed to review some new information concerning H. pylori influence on autonomic nervous system (ANS) activity as a mechanism of indirect action on the digestive tract and circulation system. Effect of H. pylori on ANS may result from the direct neurotoxic effect, activation of inflammatory processes in nerves, microelements deficiency, as well as from stimulation induced by symptoms arising from digestive and circulatory systems. ANS imbalance in H. pylori infected patients may affect esophageal motility, quantity of gastric content refluxed into esophagus, gastric emptying, gastric juice acidity and mucosal blood flow. These disturbances evoke dyspepsia, heartburn and chest pain. The last needs a special attention, because of potential fatal outcome when misdiagnosed. Determination of chest pain source may be difficult, moreover it can be multifactorial. Both esophageal and cardiac disorders, as well as interrelationships between these organs, depending on common diseases risk factors, vagal reflexes, decreased pain threshold and adverse effects of drugs applied in angina pectoris therapy should be taken into consideration.

Key words
helicobacter pylori, heart rate variability, autonomic nervous system, chest pain, digestive tract


Full text
(english)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Gastroenterología, Infectología
Relacionadas: Bioquímica, Diagnóstico por Laboratorio, Medicina Interna, Neurología



Comprar este artículo
Extensión: 10.56 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Jacek Budzynski, Department of Gastroenterology, Vascular Diseases and Internal Medicine, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz, Ujejskiego 75 Street, 85-168, Bydgoszcz, Polonia
Bibliografía del artículo
1. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127(4):1239-55, 2004.
2. Patti MG, Gorodner MV, Galvani C et al. Spectrum of esophageal motility disorders: implications for diagnosis and treatment. Arch Surg 140(5):442-8, 2005.
3. Bennett J. ABC of the upper gastrointestinal tract. Oesophagus: atypical chest pain and motility disorders. BMJ 323(7316):791-4, 2001.
4. Bercik P, De Giorgio R, Blennerhassett P, Verdu EF, Barbara G, Collins SM. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology 123(4):1205-15, 2002.
5. Budzynski J, Klopocka M, Bujak R, Swiatkowski M, Pulkowski G, Sinkiewicz W. Autonomic nervous function in Helicobacter pylori-infected patients with atypical chest pain studied by analysis of heart rate variability. Eur J Gastroenterol Hepatol 16(5):451-7, 2004.
6. Vizi ES, Elenkov IJ. Nonsynaptic noradrenaline release in neuro-immune responses. Acta Biol Hung 53(1-2):229-244, 2002.
7. Gulcelik NE, Kaya E, Demirbas B et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 28(3):214-7, 2005.
8. Swiatkowski M, Budzynski J, Klopocka M, Ziolkowski M, Bujak R, Sinkiewicz W. Parameters of the functional and morphological status of the upper digestive tract in alcohol-dependent male patients with depression and alexithymia in the context of autonomic nervous system activity and nitric oxide plasma level. Med Sci Monit 10(2):CR68-74, 2004.
9. Wilhelmsen I, Berstad A. Reduced relapse rate in duodenal ulcer disease leads to normalization of psychological distress: twelve-year follow-up. Scand J Gastroenterol 39(8):717-21, 2004.
10. Rossetto O, De Bernard M, Pellizzari R et al. Bacterial toxins with intracellular protease activity. Clin Chim Acta 291(2):189-99, 2000.
11. Malave HA, Taylor AA, Nattama J, Deswal A, Mann DL. Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. Chest 123(3):716-24, 2003.
12. Yagci M, Yamac K, Acar K, Cingi E, Kitapci M, Haznedar R. Gastric emptying in patients with vitamin B(12) deficiency. Eur J Nucl Med Mol Imaging 29(9):1125-7, 2002.
13. Kutluana U, Simsek I, Akarsu M, Kupelioglu A, Karasu S, Altekin E. Is there a possible relation between atrophic gastritis and premature atherosclerosis? Helicobacter 10(6):623-9, 2005.
14. Katoh K, Nomura M, Nakaya Y. et al. Autonomic nervous activity before and after eradication of Helicobacter pylori in patients with chronic duodenal ulcer. Aliment Pharmacol Ther 16(Suppl 2):180-6, 2002.
15. Nada T, Nomura M, Iga A. et al. Autonomic nervous function in patients with peptic ulcer studied by spectral analysis of heart rate variability. J Med 32(5-6):333-47, 2001.
16. Nomura M, Yukinaka M, Miyajima H. et al. Is autonomic dysfunction a necessary condition for chronic peptic ulcer formation? Aliment Pharmacol Ther 14(Suppl 1):82-6, 2000.
17. Lucini D, Cerchiello M, Basilisco G. et al. Autonomic control of heart period in duodenal ulcer patients: insights from spectral analysis of heart rate variability. Auton Neurosci 84(3):122-129, 2000.
18. Yukinaka M, Nomura M, Saijyo T et al. Evaluation of autonomic nervous function in patients with essential hypertension complicated with peptic ulcer. J Gastroenterol Hepatol 15(1):40-44, 2000.
19. Tougas G, Spaziani R, Hollerbach S et al. Cardiac autonomic function and oesophageal acid sensitivity in patients with non-cardiac chest pain. Gut 49(5):706-12, 2001.
20. Pirtniecks A, Smith LF, Thorpe JA. Autonomic dysfunction in non-specific disorders of oesophageal motility. Eur J Cardiothorac Surg 17(2):101-5, 2000.
22. Tillisch K, Mayer EA, Labus JS, Stains J, Chang L, Naliboff BD. Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 54(10):1396-401, 2005.
23. Willich SN, Kulig M, Muller-Nordhorn J. European survey on circadian variation of angina pectoris (ESCVA) in treated patients. Herz 29(7):665-72, 2004.
24. D'Negri CE, Marelich L, Vigo D et al. Circadian periodicity of heart rate variability in hospitalized angor patients. Clin Auton Res 15(3):223-32, 2005.
25. Kawano H, Ogawa H. Endothelial function and coronary spastic angina. Internal Medicine 44(2):91-99, 2005.
26. Dobrzycki S, Baniukiewicz A, Korecki J et al. Does gastro-esophageal reflux provoke the myocardial ischemia in patients with CAD? Int J Cardiol 104(1):67-72, 2005.
27. Dobrzycki S, Skrodzka D, Musial WJ et al. Relationship between gastroesophageal reflux disease and myocardial ischemia. Effect of reflux on temporary activity of autonomic nervous system. Rocz Akad Med Bialymst 49:93-7, 2004.
28. Swiatkowski M, Budzynski J, Klopocka M, Pulkowski G, Suppan K, Fabisiak J, Morawski W, Majer M. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med Sci Monit 10(9):CR524-529, 2004.
29. Johansson S, Wallander MA, Ruigomez A, Garcia Rodriguez LA. Is there any association between myocardial infarction, gastro-oesophageal reflux disease and acid-suppressing drugs? Aliment Pharmacol Ther 18(10):973-8, 2003.
30. Laheij RJ, Van Rossum LG, Jansen JB, Verheugt FW. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 18(1):109-15, 2003.
31. Chauhan A, Petch MC, Schofield PM. Cardio-oesophageal reflex in humans as a mechanism for 'linked angina'. Eur Heart J 17(3):407-413, 1996.
32. Caldwell MT, Byrne PJ, Marks P, Walsh TN, Hennessy TP. Bradykinin, coronary artery disease and gastro-oesophageal reflux. Br J Surg 81(10):1462-4, 1994.
33. Budzynski J, Swiatkowski M, Klopocka M, Fabisiak J, Bujak R, Sinkiewicz W. Relationship between results of electrocardiographic exercise tests and intraesophageal pH in men with atypical chest pain. Pol Arch Med Wewn 103:135-140, 2000.
34. Makk LJ, Leesar M, Joseph A, Prince CP, Wright RA. Cardioesophageal reflexes: an invasive human study. Dig Dis Sci 45(12):2451-4, 2000.
35. Lee YC, Wang HP, Lin LY. et al. Heart rate variability in patients with different manifestations of gastroesophageal reflux disease. Auton Neurosci 116(1-2):39-45, 2004.
36. Chen CL, Orr WC. Autonomic responses to heartburn induced by esophageal acid infusion. J Gastroenterol Hepatol 19(8):922-6, 2004.
37. Bhatia V, Tandon RK. Stress and the gastrointestinal tract. J Gastroenterol Hepatol 20(3):332-9, 2005.
38. Ambepityia G, Kopelman PG, Ingram D, Swash M, Mills PG, Timmis AD. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 15(1):72-7, 1990.
38. Bass C, Mayou R. ABC of psychological medicine. Chest Pain BMJ 325:588-591, 2002.
39. Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. JAMA 293(4):477-84, 2005.
40. Katerndahl D. Panic & plaques: panic disorder & coronary artery disease in patients with chest pain. J Am Board Farm Pract 17(2):114-26, 2004.
41. Tsai SH, Chen CM, Chang CS, Chen GH. Effect of Helicobacter pylori infection on intragastric acidity in patients with reflux esophagitis. J Gastroenterol 39(9):821-6, 2004.
42. Giral A, Celikel CA, Ozdogan O, Tozun N, Ulusoy NB, Kalayci C. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. J Gastroenterol Hepatol 20(12):1886-91, 2005.
43. Ando T, El-Omar EM, Goto Y et al. IL-1 beta pro-inflammatory genotypes protect against gastro-oesophageal reflux disease through induction of corpus atrophy. Gut 2005.
44. Delaney B, McColl K. Review article: Helicobacter pylori and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 22(Suppl 1):32-40, 2005.
45. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 18(1):20-6, 2000.
46. Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain- a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 19(10):1123-30, 2004.
47. Dickman R, Emmons S, Cui H et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 22(6):547-55, 2005.
48. Zerbib F, Bicheler V, Leray V, Joubert M, Bruley des Varannes S, Galmiche JP. H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. Am J Physiol Gastrointest Liver Physiol 281(2):G350-6, 2001.
49. Tanaka I, Tatsumi Y, Kodama T et al. Effect of Helicobacter pylori eradication on gastroesophageal function. J Gastroenterol Hepatol 19(3):251-7, 2004.
50. Spence JD, Norris J. Infection, inflammation, and atherosclerosis. Stroke 34(2):333-4, 2003.
51. Kowalski M. Helicobacter pylori infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol 52(1 Suppl 1):3-31, 2001.
52. Kaplan M, Yavuz SS, Cinar B et al. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis 2005.
53. Oshima T, Ozono R, Yano Y. et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. Am Coll Cardiol 45(8):1219-22, 2005.
54. Kanbay M, Gur G, Yucel M, Yilmaz U, Boyacioglu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci 50(7):1228-31, 2005.
55. Migneco A, Ojetti V, Specchia L. et al. Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter 8(6):585-9, 2003.
56. Cassar K, Bachoo P, Ford I, McGee M, Greaves M, Brittenden J. Helicobacter pylori seropositivity is associated with enhanced platelet activation in patients with intermittent claudication. J Vasc Surg 39(3):560-4, 2004.
57. Colucci M, Rossiello MR, Pentimone A et al. Changes in coagulation-fibrinolysis balance in blood mononuclear cells and in gastric mucosa from patients with Helicobacter pylori infection. Thromb Res 116(6):471-7, 2005.
58. Aydemir S, Bayraktaroglu T, Sert M et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 50(11):2090-3, 2005.
59. Kratnov AE, Pavlov ON. Helicobacter pylori infection and state of antioxidant protection in patients with the unstable course of ischemic disease. Eksp Klin Gastroenterol 5(4-9):145, 2004.
60. Montenero AS, Mollichelli N, Zumbo F. et al. Helicobacter pylori and atrial fibrillation: a possible pathogenic link. Heart 91(7):960-1, 2005.
61. Whittle BJ, Morschl E, Pozsar J, Moran AP, Laszlo F. Helicobacter pylori lipopolysaccharide provokes iNOS-mediated acute systemic microvascular inflammatory responses in rat cardiac, hepatic, renal and pulmonary tissues. J Physiol Paris 95(1-6):257-9, 2001.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618